Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. - Test2 - elhamkhani - TriplyDB

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

http://www.wikidata.org/entity/Q35130666

about

A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1 Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?Innovations in phenotyping of mouse models in the German Mouse Clinic.MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.A cross-species analysis method to analyze animal models' similarity to human's disease state.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Current assessment of polo-like kinases as anti-tumor drug targets.The role of Plk3 in oncogenesis.Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8.Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis FcγRIIb on liver sinusoidal endothelium clears small immune complexes.Mitotic Kinases and p53 Signaling.Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells.The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.Polo-like kinases in AML.PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

P2860

Q27304385-4BAC0B5D-A558-4561-AB2A-EE9DABE93B19 Q27684872-75ECDF00-5F2C-468A-A0DB-5ABA48714A41 Q28262425-1C270BE3-EDD2-4F05-9D55-795BD66E0010 Q30485660-CF3ED74A-4CCE-4469-8C25-D352D89ED951 Q34476639-2D4B3924-A3AA-4D7B-B7D5-AC956C4225FC Q34530293-9ADD1081-51DF-48D5-851F-A1202D7FDBE5 Q36062154-66243E93-B2C5-40AA-8988-17939FD1E13D Q36289531-2EC51BD0-D323-4DA6-A440-48C74241A7C5 Q36386336-F7ADF959-9F40-4860-BABA-B1EEA0193672 Q36781191-7AD2E8B2-4226-47FB-AF7E-C22E56BF7155 Q37302721-EC54217A-8840-44A1-82AC-7C2C24C77DDB Q37398885-BEB91EC3-CC37-416C-AC34-0C3105513A22 Q37994256-600DB6C8-4283-423A-8D82-FA682BB36A52 Q38129174-CA985550-26E0-4759-809D-519406ED07CC Q38211244-B428EBB3-C804-4BAC-89CB-861A68AA827B Q38444150-A596C242-280C-4EF0-ABA0-5576C625FC65 Q38718733-71E40D6E-4757-4ABF-B51B-BA7F15F9F358 Q38842267-AE9AB051-B437-46BE-B1F5-C8101685D89E Q38961886-332602CE-1BDE-413B-8133-2FD88B03E5E2 Q38973171-70500682-B3C6-4D28-B144-76CA3F8A55A3 Q39042925-17575B2E-1573-45D3-80DE-0ADBE15A7064 Q39141522-66C23C26-283A-48EF-87C4-039847D0AEEC Q39601527-D17CF981-66D1-4E27-9D6C-722B00D6B1ED Q39668561-82E049AF-F217-4AB9-A822-09F397D5798C Q41135486-07711612-8959-4251-AD1B-F40ED09A621B Q41888418-3E0036F9-A707-4FC3-88EF-265F657F5110 Q42254103-3B1C59A6-4759-4BC1-986F-E1BAF2A9E4B5 Q42329961-C904E9CC-7AE0-4A8F-9E79-5882C61E7A03 Q42777655-00F3F48E-F76C-4F08-A30A-35A40AE718D5 Q42858044-6D9D383A-D5FD-4186-8622-70E001EFFD06 Q45068538-9DC5A619-C2EF-4522-9359-B47FFE683069 Q46455146-F0FFAA38-5BBD-473B-AD2B-D9DB4CC5A336 Q50939437-6239B74D-58F6-4800-8418-E70E5E35AC24 Q52352270-BF47C48B-E1C5-4133-9E53-3D7879609035 Q53015871-F9EC1719-9235-465E-86DF-445CF4F1DDDF Q55054132-2234AC51-74D6-4B2A-9AFA-836D04E803DE Q57809711-D4E98F81-8CF0-4046-8136-B9E4F5AF3B38 Q58920117-45F21E0E-25B0-44CA-B0B6-102F34EC2DBE

P2860

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

http://www.wikidata.org/entity/Q35130666

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@ast

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@en

type

label

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@ast

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@en

prefLabel

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@ast

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@en

P1433

Q35130666-43715617-DA4B-4189-B28A-19857303C067

P1476

Q35130666-AEA63BE8-2D67-44C2-BCAA-D9E44084CAC1

P2093

Q35130666-0C3A538B-61A5-495C-823A-A1581E7FAB11

Q35130666-10041F82-E089-43D1-9669-69D404802B35

Q35130666-2BD71710-AC29-4A0F-9710-7F2A365E1B3A

Q35130666-386B8EB7-37D7-4D22-B214-AF1FC0BD6FA6

Q35130666-47D99B19-ABD1-4AA5-8DD2-088C9FE62B78

Q35130666-49A03D46-206F-461E-8D75-849166F4319E

Q35130666-5971C613-EB41-498E-97E6-5D097E07961F

Q35130666-5C62B91D-BC2A-45A2-82C8-62614445C144

Q35130666-619C3C72-2DE9-4335-89CE-F93E1B411B1A

Q35130666-707D8CCC-8979-4229-9A63-DF3757BC6EDD

P2860

Q35130666-090CD114-CB61-4965-826F-111DE8E6D11F

Q35130666-1B190933-2B7B-4C2D-8CBD-5E23EDBD0974

Q35130666-1B5F6EAB-3E50-44BA-8EC9-9B2FFDC229A3

Q35130666-2442A66F-6C3F-46EA-BFBA-18027813702B

Q35130666-25DBF798-CB2F-4471-AA37-2F28F6D1BEC3

Q35130666-2B2F462C-73BC-4097-A295-387EF9C056B3

Q35130666-334DBA95-1306-4734-9853-ECF4BD685B6D

Q35130666-383C11E3-D6E8-43D6-8FE0-E2561DC3C0AE

Q35130666-39713D0F-949A-4752-A864-CFF715A04476

Q35130666-3D293A01-2B8C-437A-AA75-5B3EADA6D7CC

P2888

Q35130666-978AB3A2-EA5B-4A7F-AE73-88513D6FA70B

P304

Q35130666-66041B66-A398-43EB-98E1-8F02793117CE

P31

Q35130666-F25419A3-EEEE-4FED-BD9E-4E37976AD0F8

P356

Q35130666-9D517A25-2A56-4DCE-A501-4D34F13BA769

P407

Q35130666-F7328109-25D8-49F4-BA57-790BE6D9DAA8

P478

Q35130666-F06434D7-B844-4463-8146-7666DB5EFAED

P50

Q35130666-4188B557-D31A-4C84-8346-E441ACE47E25

Q35130666-56BCB139-7775-4B6A-84AC-65119A8EAFB8

Q35130666-67249AD4-4202-4C0F-9378-7D04100B19D6

Q35130666-71506F82-4795-492D-947A-A32418AF0C1D

Q35130666-7D2D100C-C687-42A1-96A7-670ED927B9C6

Q35130666-8C877146-5D07-4C40-A7B8-9FDE8F5871B3

Q35130666-A063F60B-1E2E-4AEB-A0F9-9430C8A5DBCC

P577

Q35130666-8DA08D66-2E5C-4D55-A9AB-40EA25451BD6

P5875

Q35130666-D65D4608-D7E9-4015-A3CD-DC7A0C1B46E8

P698

Q35130666-08D09CC3-2EA6-4C72-8C3A-A53F8BCC68DC

P932

Q35130666-2E62554E-79F1-4934-8CBE-B7187E7CAF7E

P356

P1433

Nature Communications

P1476

Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.

@en

P2093

Andrea Krämer

http://www.w3.org/2001/XMLSchema#string

Bertolt Kreft

http://www.w3.org/2001/XMLSchema#string

Birgit Rathkolb

http://www.w3.org/2001/XMLSchema#string

Dirk H Busch

http://www.w3.org/2001/XMLSchema#string

Elisabeth Kurunci-Csacsko

http://www.w3.org/2001/XMLSchema#string

Florian Prinz

http://www.w3.org/2001/XMLSchema#string

Helmut Fuchs

http://www.w3.org/2001/XMLSchema#string

Jost Seibler

http://www.w3.org/2001/XMLSchema#string

Juping Yuan

http://www.w3.org/2001/XMLSchema#string

Klaus Strebhardt

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes

Single copy shRNA configuration for ubiquitous gene knockdown in mice

The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro

The spindle-assembly checkpoint in space and time

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions

Polo-like kinases and the orchestration of cell division

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

All you wanted to know about spermatogonia but were afraid to ask.

Polo-like kinases and oncogenesis.

P2888

P304

395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS1395

http://www.w3.org/2001/XMLSchema#string

P407

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Martin Klingenspor

Martin Hrabě de Angelis

Valérie Gailus-Durner

Julia Calzada-Wack

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51505147

http://www.w3.org/2001/XMLSchema#string

P698

21772266

http://www.w3.org/2001/XMLSchema#string

P932

3144583

http://www.w3.org/2001/XMLSchema#string